Filing Details

Accession Number:
0001209191-24-005522
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-03 20:51:05
Reporting Period:
2024-05-03
Accepted Time:
2024-05-03 20:51:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1607678 Viking Therapeutics Inc. VKTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1264949 Greg Zante C/O Viking Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 350
San Diego CA 92121
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.00001 Per Share Acquisiton 2024-05-03 4,249 $4.68 211,610 No 4 M Direct
Common Stock, Par Value $0.00001 Per Share Acquisiton 2024-05-03 30,000 $4.88 241,610 No 4 M Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-05-03 3,101 $73.49 238,509 No 4 S Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-05-03 45,570 $74.44 192,939 No 4 S Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-05-03 17,238 $75.49 175,701 No 4 S Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-05-03 847 $76.07 174,854 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-05-03 4,249 $0.00 4,249 $4.68
Common Stock Stock Option (Right to Buy) Disposition 2024-05-03 30,000 $0.00 30,000 $4.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,251 2021-03-31 2030-03-31 No 4 M Direct
60,000 2023-01-03 2032-01-03 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.985 to $75.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.995 to $76.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  6. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date.